Skip to main content

Table 1 Characteristics of mothers and children in the control and DHA-supplemented groups

From: Effect of prenatal DHA supplementation on the infant epigenome: results from a randomized controlled trial

 

Newborn subset for 450K BeadChip (n = 369)

All newborns (n = 991)

DHA group (n = 190)

Control group (n = 179)

DHA group (n = 517)

Control group (n = 474)

Recruitment hospital

 Flinders Medical Centre and private hospitals, no. (%)

59 (31.1)

64 (35.8)

199 (38.5)

188 (39.7)

 Women’s and Children’s Hospital, no. (%)

131 (68.9)

115 (64.2)

318 (61.5)

286 (60.3)

Primiparous, no. (%)

68 (35.8)

60 (33.5)

212 (41.0)

192 (40.5)

Mother’s age at trial entry, mean (SD), years

30.2 (5.9)

30.2 (5.5)

29.8 (5.6)

29.7 (5.5)

Mother smoking at trial entry, no. (%)

19 (10.0)

15 (8.4)

60 (11.6)

52 (11.0)

Duration of gestation, median (IQR), weeks

39.9 (38.6–40.7)

39.7 (39–40.5)

39.7 (38.7–40.7)

39.6 (38.9–40.4)

Birth weight, median (IQR), g

3542 (3160–3859)

3510 (3260–3832)

3500 (3160–3820)

3510 (3190–3798)

Child male sex, no. (%)

92 (48.4)

93 (52.0)

260 (50.3)

242 (51.1)

DHA in cord blood, mean (SD), % of total fatty acids

7.9 (1.8)*

6.4 (1.5)

7.8 (1.8)*

6.3 (1.5)

  1. Abbreviations: DHA docosahexaoneic acid, IQR interquartile range
  2. *Difference between the DHA and control group P < 0.001